Hospital
Northeast Hospital Corporation
Northeast Hospital Corporation was paid $2.53M by Medicaid between Apr 2019 and Feb 2020, across 151 billing codes. Its largest line is 92507, Treatment of speech, language, voice, communication, and/or auditory processing disorder — 12% of everything it billed.
33Billing provider infoNORTHEAST HOSPITAL CORPORATION
BEVERLY, MA 01915
BEVERLY, MA 01915
33aNPI1407827710assigned 01/27/2006
33bProvider typePsychiatric Hospital Unit
28Total paid$2.53M
24GClaims43,133
24DCodes billed151
24AFirst – last monthApr 2019 – Feb 2020
Compared with peers
Next to other Psychiatric Hospital Unit providers in Massachusetts
Rank by total paid#6 of 27
Median peer was paid$138K
This provider vs. median18×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 37,379 | $2.29M | |
| 2020 | 5,754 | $239K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 12% | 1,572 | 453 | $292K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10% | 1,118 | 1,079 | $265K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 9.8% | 1,673 | 548 | $247K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.5% | 950 | 895 | $239K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 7.9% | 875 | 750 | $198K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 4.2% | 496 | 421 | $106K |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.7% | 255 | 235 | $93K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.4% | 372 | 362 | $85K |
| 77063 | Screening digital breast tomosynthesis, bilateral | 3.3% | 411 | 411 | $84K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 2.7% | 326 | 301 | $68K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.3% | 1,222 | 829 | $59K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 2.0% | 1,140 | 408 | $50K |
139 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.0% | 213 | $50K |
| 71046 | Radiologic examination, chest; 2 views | 1.8% | 589 | $44K |
| 97010 | 1.4% | 207 | $36K | |
| G0378 | Hospital observation service, per hour | <1% | 169 | $24K |
| H0015 | Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education | <1% | 79 | $24K |
| 80053 | Comprehensive metabolic panel | <1% | 1,796 | $24K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 160 | $22K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 675 | $22K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 660 | $21K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 350 | $20K |
| 97803 | <1% | 93 | $18K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 176 | $18K |
| 59025 | Fetal non-stress test | <1% | 73 | $18K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 67 | $17K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 280 | $17K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 1,915 | $15K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 859 | $15K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 195 | $15K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 162 | $14K |
| 99218 | <1% | 51 | $14K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 85 | $14K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 425 | $13K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 102 | $13K |
| 80061 | Lipid panel | <1% | 1,257 | $12K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 381 | $10K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 27 | $10K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 302 | $9K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 910 | $8K |
| 80050 | General health panel | <1% | 420 | $7K |
| 85027 | <1% | 1,084 | $7K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 610 | $7K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 696 | $7K |
| 97162 | <1% | 102 | $7K | |
| 84702 | <1% | 437 | $7K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 272 | $6K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 744 | $6K |
| 76642 | <1% | 69 | $6K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 36 | $6K |
| 82607 | <1% | 344 | $5K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 45 | $5K |
| J3490 | Unclassified drugs | <1% | 62 | $5K |
| 82728 | <1% | 326 | $5K | |
| 73630 | <1% | 58 | $4K | |
| 76536 | <1% | 12 | $4K | |
| 84153 | <1% | 199 | $4K | |
| 73610 | <1% | 51 | $3K | |
| 87081 | <1% | 493 | $3K | |
| 84484 | <1% | 244 | $3K | |
| 84466 | <1% | 243 | $3K | |
| 86803 | <1% | 230 | $3K | |
| 86618 | <1% | 181 | $3K | |
| 86780 | <1% | 219 | $3K | |
| 84439 | <1% | 300 | $3K | |
| 83516 | <1% | 72 | $3K | |
| 76770 | <1% | 18 | $3K | |
| 85610 | <1% | 646 | $3K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 32 | $3K |
| 83690 | <1% | 372 | $3K | |
| 81003 | <1% | 986 | $2K | |
| 87340 | <1% | 214 | $2K | |
| 72100 | <1% | 12 | $2K | |
| 87186 | <1% | 212 | $2K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 12 | $2K |
| 83735 | <1% | 303 | $2K | |
| 87070 | <1% | 231 | $2K | |
| 87088 | <1% | 243 | $2K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 529 | $2K |
| 73130 | <1% | 13 | $2K | |
| 87660 | <1% | 92 | $2K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 32 | $2K |
| 87480 | <1% | 91 | $2K | |
| 87510 | <1% | 91 | $2K | |
| 83540 | <1% | 264 | $2K | |
| 87147 | <1% | 179 | $2K | |
| 80076 | <1% | 203 | $2K | |
| 82248 | <1% | 609 | $2K | |
| 84403 | <1% | 51 | $2K | |
| 86140 | <1% | 278 | $1K | |
| 81025 | <1% | 225 | $1K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 129 | $1K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 371 | $1K |
| 73110 | <1% | 26 | $1K | |
| 82565 | <1% | 173 | $1K | |
| 87077 | <1% | 133 | $1K | |
| 97161 | <1% | 16 | $1K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 27 | $1K |
| 86762 | <1% | 73 | $1K | |
| 85730 | <1% | 156 | $984.75 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 66 | $854.51 |
| 82043 | <1% | 145 | $838.75 | |
| 74018 | <1% | 13 | $796.52 | |
| 88342 | <1% | 55 | $743.19 | |
| 71045 | Radiologic examination, chest; single view | <1% | 130 | $693.70 |
| 82962 | <1% | 449 | $673.50 | |
| 82947 | <1% | 137 | $526.00 | |
| 85652 | <1% | 186 | $516.04 | |
| 87522 | Neg quan hep c or qual rna | <1% | 13 | $507.91 |
| 84550 | <1% | 187 | $454.76 | |
| 86706 | <1% | 37 | $431.14 | |
| 86850 | <1% | 15 | $429.00 | |
| 84460 | <1% | 109 | $406.98 | |
| 84270 | <1% | 15 | $398.25 | |
| 84450 | <1% | 96 | $356.04 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 459 | $354.66 |
| 82784 | <1% | 26 | $353.00 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 327 | $343.07 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 313 | $312.29 |
| 85379 | <1% | 27 | $302.14 | |
| 83001 | <1% | 12 | $272.40 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 41 | $263.47 |
| 87205 | <1% | 49 | $262.94 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 539 | $255.92 |
| 84520 | <1% | 97 | $229.40 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 118 | $200.50 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 140 | $200.50 |
| 86704 | <1% | 13 | $191.49 | |
| 87040 | <1% | 15 | $160.41 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 159 | $145.55 |
| 86787 | <1% | 12 | $141.00 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 29 | $132.16 |
| 77065 | Tomosynthesis, mammo | <1% | 14 | $132.16 |
| J2704 | Injection, propofol, 10 mg | <1% | 233 | $109.90 |
| 84100 | <1% | 40 | $101.28 | |
| 84156 | <1% | 18 | $80.64 | |
| 85018 | <1% | 12 | $33.19 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 0% | 418 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 333 | $0.00 |
| 99152 | 0% | 40 | $0.00 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 95 | $0.00 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 17 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 17 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 12 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 88 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 166 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 146 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 120 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 41 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 21 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCONROY, DENIS (CEO)
| Provider | Location | Paid |
|---|---|---|
| Northeast Hospital Corporation | Beverly, MA | $289K |
| Northeast Hospital Corporation | Danvers, MA | $3K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.